...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Antibiotics: An International Journal >Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
【24h】

Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps

机译：抗生素药物发现和发展的激励创新：进步，挑战和下一步

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms.
机译：对抗抗微生物抵抗（AMR）的政治动力和资金继续构建。已经实施了众多主要的国际和国家旨在经济上激励抗生素的研究和开发（R＆D）的主要国际和国家举措。然而，仍然尚不清楚如何有效加强当前的激励计划，以进一步加速抗生素创新。该研究首先根据文献综述和专家投入，首先识别并评估了主要的国际，欧盟，美国和英国抗生素研发资金计划。然后在全面改善抗生素市场的市场和公共卫生标准中评估这些计划。目前的激励计划是提高抗生素发育经济可行性的重要初步步骤。但是，似乎缺乏各种倡议的全球协调，这会努力复制努力，在价值链中留下资金差距并忽视重要的AMR目标。本研究发现，激励计划过于致力于早期推动基础科学和临床前研究的早期推动资金，而临床发展的有限推动资金有限。此外，几乎没有拉动激励措施，以促进从早期临床阶段转变抗生素产物，以商业化，焦点显影剂浓度在最高优先级抗生素上，并吸引大型制药公司投资市场。最后，似乎抗生素可持续性和患者接入要求都集成到激励机制阵列中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号